The rates of adverse events (AE) and infections were not different according to the type of biologics (AE mean rate: 11.3 (CI 95% 9.9–12.7)/100 pts years; p = 0.11, infection mean rate: 9.5 (CI 95% 8.4–10.6)/100 pts years; p = 0.56) in elderly IBD patients with the use of anti-TNF, VDZ, or UST. This evidence concerns the gene TNF and inflammatory bowel disease.